Hartline Investment Corp Has $12.79 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Hartline Investment Corp lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% during the 4th quarter, HoldingsChannel reports. The fund owned 21,934 shares of the company’s stock after acquiring an additional 248 shares during the quarter. Eli Lilly and Company accounts for approximately 2.1% of Hartline Investment Corp’s holdings, making the stock its 13th largest position. Hartline Investment Corp’s holdings in Eli Lilly and Company were worth $12,786,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Simon Quick Advisors LLC grew its stake in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $363,000. WASHINGTON TRUST Co boosted its stake in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after purchasing an additional 2,671 shares in the last quarter. Liontrust Investment Partners LLP acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $8,326,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after purchasing an additional 18,079 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $13.49 during midday trading on Wednesday, reaching $732.20. The stock had a trading volume of 2,063,476 shares, compared to its average volume of 3,038,542. The firm’s 50-day moving average price is $763.89 and its 200 day moving average price is $664.05. Eli Lilly and Company has a 12 month low of $370.68 and a 12 month high of $800.78. The firm has a market capitalization of $695.71 billion, a PE ratio of 126.78, a P/E/G ratio of 1.59 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.